[HTML][HTML] Innate immunity mediated by TLR9 modulates pathogenicity in an animal model of multiple sclerosis

M Prinz, F Garbe, H Schmidt, A Mildner… - The Journal of …, 2006 - Am Soc Clin Investig
M Prinz, F Garbe, H Schmidt, A Mildner, I Gutcher, K Wolter, M Piesche, R Schroers, E Weiss
The Journal of clinical investigation, 2006Am Soc Clin Investig
Inflammatory diseases of the CNS, such as MS and its animal model EAE, are characterized
by infiltration of activated lymphocytes and phagocytes into the CNS. Within the CNS,
activation of resident cells initiates an inflammatory cascade, leading to tissue destruction,
demyelination, and neurologic deficit. TLRs recognize microbes and are pivotal mediators of
innate immunity. Within the CNS, augmented TLR expression during EAE is observed, even
in the absence of any apparent microbial involvement. To determine the functional …
Inflammatory diseases of the CNS, such as MS and its animal model EAE, are characterized by infiltration of activated lymphocytes and phagocytes into the CNS. Within the CNS, activation of resident cells initiates an inflammatory cascade, leading to tissue destruction, demyelination, and neurologic deficit. TLRs recognize microbes and are pivotal mediators of innate immunity. Within the CNS, augmented TLR expression during EAE is observed, even in the absence of any apparent microbial involvement. To determine the functional relevance of this phenomenon during sterile autoimmunity, we studied the role of different TLRs as well as their common signaling adaptor MyD88 in the development of EAE. We found that MyD88–/– mice were completely EAE resistant. Surprisingly, this protection is partly due to engagement of the CpG receptor TLR9. Restricting the MyD88 or TLR9 mutation to host radio-resistant cells, including the cells within the CNS, revealed that engagement of radio-resistant cells modulated the disease course and histopathological changes. Our data clearly demonstrate that both TLR9 and MyD88 are essential modulators of the autoimmune process during the effector phase of disease and suggest that endogenous “danger signals” modulate the disease pathogenesis.
The Journal of Clinical Investigation